Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Senate questions for Henney

This article was originally published in The Gray Sheet

Executive Summary

FDA Commissioner-nominee Jane Henney, MD, is asked to provide her "general understanding" of FDA's policy regarding advertising and promoting laser-assisted in situ keratomileusis (LASIK) procedures with unapproved "black box" lasers and approved lasers. The question is one of 24 submitted to the nominee on Oct. 1 by Sen. Orrin Hatch (R-Utah.), who also asks Henney whether it would be in the interest of "public health if an [over-the-counter] home drug analysis test kit came on the market." In addition to the questions, Hatch requests a meeting with Henney to discuss her responses, the need for which could postpone the Senate's consideration of the nomination past the target adjournment date of Oct. 9

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel